Development of a Metastatic Uveal Melanoma Prognostic Score (MUMPS) for Use in Patients Receiving Immune Checkpoint Inhibitors

Metastatic uveal melanoma (mUM) is a rare disease. There are limited data on prognostic clinical factors for overall survival (OS) in patients with mUM treated with immune checkpoint inhibitors (ICI). Retrospective and non-randomized prospective studies have reported response rates of 0–17% for anti...

Full description

Saved in:
Bibliographic Details
Published in:Cancers 2021-07, Vol.13 (14), p.3640
Main Authors: Kelly, Deirdre, Rose, April A. N., Muniz, Thiago Pimentel, Hogg, David, Butler, Marcus O., Saibil, Samuel D., King, Ian, Kamil, Zaid Saeed, Ghazarian, Danny, Ross, Kendra, Iafolla, Marco, Araujo, Daniel V., Waldron, John, Laperriere, Normand, Krema, Hatem, Spreafico, Anna
Format: Article
Language:English
Subjects:
Cancer therapies
Chromosomes
Clinical trials
CTLA-4 protein
Data analysis
Decision making
Diagnosis
Disease control
Health care networks
Immune checkpoint inhibitors
Medical prognosis
Medical records
Melanoma
Metastases
Metastasis
Mumps
Patients
PD-1 protein
Prognosis
Regression analysis
Response rates
Statistical analysis
Survival
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Metastatic uveal melanoma (mUM) is a rare disease. There are limited data on prognostic clinical factors for overall survival (OS) in patients with mUM treated with immune checkpoint inhibitors (ICI). Retrospective and non-randomized prospective studies have reported response rates of 0–17% for anti-PD1/L1 ± anti-CTLA4 ICI in mUM, indicating a potential benefit only in a subset of patients. This study evaluates the characteristics associated with ICI benefit in patients with mUM. We performed a single-center retrospective cohort study of patients with mUM who received anti-PD1/L1 ± anti-CTLA4 ICI between 2014–2019. Clinical and genomic characteristics were collected from a chart review. Treatment response and clinical progression were determined by physician assessment. Multivariable Cox regression models and Kaplan–Meier log-rank tests were used to assess differences in clinical progression-free survival (cPFS) and OS between groups and identify clinical variables associated with ICI outcomes. We identified 71 mUM patients who received 75 lines of ICI therapy. Of these, 54 received anti-PD1/L1 alone, and 21 received anti-PD1/L1 + anti-CTLA4. Patient characteristics were: 53% female, 48% were 65 or older, 72% received one or fewer lines of prior therapy. Within our cohort, 53% of patients had developed metastatic disease
ISSN:2072-6694
2072-6694
DOI:10.3390/cancers13143640